#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gestational trophoblastic tumour Metastases to central nervous system Hepatitis B Autoimmune hepatitis Noonan syndrome Ocular myasthenia SAPHO syndrome Asthma Leiomyosarcoma recurrent Pseudoxanthoma elasticum Anti-myelin-associated glycoprotein antibodies positive Undifferentiated sarcoma Gaucher's disease type I Central nervous system lymphoma Transplant rejection More trials…

    Learn about Rare Diseases

    Sjogren’s syndrome – Life with Disease Leiomyosarcoma – Life with Disease SAPHO syndrome – Basic Information Arterial tortuosity syndrome – Trials in Disease Rett syndrome – Trials in Disease Toxic epidermal necrolysis – Basic Information Marfan’s syndrome – Trials in Disease Angelman’s syndrome – Basic Information Haemophilia – Basic Information Glomerulonephritis membranoproliferative – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dexibuprofen Buprenorphine Ng004 Dobutamine Hydrochloride Sultiame Isoniazid Landiolol Hydrochloride ZILUCOPLAN Trientine Dihydrochloride Ginisortamab Absk021 Hydrochloride Hydrate Elacestrant Follitropin Beta Tebentafusp Sodium Glycocholate Nadunolimab Ethanol (96 Per Cent) Osilodrostat Rilpivirine Hydrochloride Tramadol More therapies…

    Learn about Your Condition

    Multiple sclerosis relapse Peritoneal abscess Psychological trauma Measles Food allergy Palpitations Tachypnoea Nodal osteoarthritis Pleural mesothelioma Rectal neoplasm Genital infection female Toxic epidermal necrolysis Lip and/or oral cavity cancer Pancoast's tumour Neoplasm malignant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nodal marginal zone B-cell lymphoma

  • Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Marginal zone lymphoma
    Investigated Drugs:
    • Epcoritamab
    Germany
  • Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Marginal zone lymphoma
    Investigated Drugs:
    • Obinutuzumab
    Germany
  • Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Copanlisib Dihydrochloride
    • Rituximab
    Germany
  • Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • B-cell lymphoma
    Investigated Drugs:
    • Lisocabtagene Maraleucel
    Austria France Germany Italy Spain Sweden

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!